Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Thalidomide for the treatment of chronic refractory pruritus
Divya Sharma
, Shawn G. Kwatra
School of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
28
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Thalidomide for the treatment of chronic refractory pruritus'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Thalidomide
100%
Chronic Pruritus
100%
Pruritus
50%
Neuromodulators
12%
Medical Literature
12%
Systemic Disease
12%
Difficult-to-treat
12%
Case-controlled
12%
Paraneoplastic
12%
Immunomodulator
12%
Risk Profile
12%
Autoimmune
12%
Dermatological Diseases
12%
Systemic Therapy
12%
Primary Biliary Cirrhosis
12%
Conservative Therapy
12%
Open-label Trial
12%
Role-based
12%
Topical Antihistamines
12%
Antipruritic Effect
12%
Actinic Prurigo
12%
Antipruritic
12%
Uremic Pruritus
12%
Prurigo Nodularis
12%
Topical Corticosteroids
12%
Adverse Risk
12%
Antipruritic Agents
12%
Medicine and Dentistry
Pruritus
100%
Thalidomide
100%
Antipruritic
37%
Topical Corticosteroid
12%
Systemic Therapy
12%
Systemic Disease
12%
Histamine Antagonist
12%
Conservative Treatment
12%
Immunomodulating Agent
12%
Dermatological Agent
12%
Autoimmunity
12%
Primary Biliary Cirrhosis
12%
Open-Label Trial
12%
Prurigo
12%
Prurigo nodularis
12%
Uremic Pruritus
12%
Pharmacology, Toxicology and Pharmaceutical Science
Thalidomide
100%
Pruritus
100%
Antipruritic Agent
37%
Antihistaminic Agent
12%
Topical Corticosteroid
12%
Immunomodulating Agent
12%
Dermatological Agent
12%
Systemic Disease
12%
Open-Label Trial
12%
Primary Biliary Cirrhosis
12%
Neurodermatitis
12%
Prurigo
12%